Roles of CDK12/CDK13 and development of inhibitors and degraders
Authors:
Open Access
- 12 February 2026
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119077
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82404666)
- National Natural Science Foundation of China (82260691)
- National Natural Science Foundation of China (202401AT070171)
- Kunming Medical University
- Yunnan Provincial Science and Technology Department
This publication has 152 references indexed in Scilit:
- Rational Design of CDK12/13 and BRD4 Molecular Glue DegradersAngewandte Chemie International Edition, 2025
- Roles of CDK12 mutations in PCa development and treatmentBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- The CDK12–BRCA1 signaling axis mediates dinaciclib‐associated radiosensitivity through p53‐mediated cellular senescenceMolecular Oncology, 2024
- Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or p38α MAPK selectivityBiochemical and Biophysical Research Communications, 2024
- Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapyActa Pharmaceutica Sinica B, 2021
- Targeting autophagy-related protein kinases for potential therapeutic purposeActa Pharmaceutica Sinica B, 2020
- Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinomaBiochemical and Biophysical Research Communications, 2019
- Structure‐Based Design of Selective Noncovalent CDK12 InhibitorsChemMedChem, 2017
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breastThe Journal of Pathology, 2014
- Flavopiridol displays preclinical activity in acute lymphoblastic leukemiaPediatric Blood & Cancer, 2007